GSK joins pharma giants dropping anti-TIGIT drugs. The news may come as a shock to the oncology field, as GSK and iTeos provided the first data for the GALAXIES Lung-201 study at the European ...

GSK has stopped development of anti-TIGIT antibody belrestotug. The Big Pharma and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

GSK said that the EOS-448/Jemperli combination will start a large randomised trial next year, adding that it now has drug candidates addressing "all three known CD226 checkpoints – TIGIT, CD96 ...

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...

When added to GSK’s drug Jemperli, the immunotherapy, known as belrestotug and aimed at a cellular target called TIGIT, didn’t meet preset criteria for progression-free survival compared to ...

Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target. Results come amid broader doubts about the approach among some. Manage alerts for this article; ...

TIGITs took another tumble with GSK plc’s decision to end a development program and a collaboration with Iteos Therapeutics Inc. New top-line results from a phase II study in non-small-cell lung ...

iTeos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am rating RCUS stock a Hold for now.

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...